Dorzamed (Eye Drops)
Each ml contains dorzolamide (in the form of hydrochloride) 20 mg.
- Increased intraocular pressure;
- Open-angle glaucoma (including pseudoexfoliative glaucoma and other types of
secondary open-angle glaucoma).
- Hypersensitivity to drug components;
- Severe renal insufficiency (CC less than 30 ml/min);
- Hyperchloremic acidosis;
- Pregnancy and lactation period;
- Child age.
Topical reactions: burning, pricking, itching in eyes, visual blurring, eyelid
irritation, conjunctivitis, blepharitis; seldom – iridocyclitis.
Systemic reactions: bitter taste in mouth is possible, nausea, headache,
paresthesia, asthenia, sinusitis, rhinitis, nephrourolithiasis, hypersensitivity
reactions (including appearance of skin rash, angioneurotic edema, bronchospasm).
DOSAGE AND ADMINISTRATION
Only for topical application. Conjunctivally. At monotherapy Dorzamed is
administered by 1 drop in each affected eye 3 times per day.
In combination with beta-adrenoblockers for topical administration the
preparation is administered by 1 drop in each affected eye 2 times per week.
During concomitant application of other topical ophthalmological agents the
interval between instillations can be less than 10 minutes. In case of shifting
from treatment with other ophtalmological preparation to Dorzamed, the
preparation is cancelled after usual daily dosage, and treatment with Dorzamed
is started the next day.
Dorzolamide potentiates the effect of other Anti-glaucoma. Acetazolamide
increases the risk of Dorzamed systemic adverse effects development during oral
administration. The effect of such acetylcholinesterase inhibitors, as
physostigmine, galantamine, neostigmine or pyridostigmine (often used at
myasthenia) may be decreased by dorzolamide. At combined application with
diuretics significant potassium loss is possible. During concomitant application
with phenytoin osteoporosis may worsen.
Eye drops Dorzamed contain a preservative, therefore persons, wearing contact
lenses, should take off them before drug administration and insert them again
not earlier then 15 minute after instillation.
5 ml in plastic vial with dropping stopper and screw cap, supplied with guard
ring. Vial in carton box with packaging leaflet.